Dataset for longitudinal evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG assays in a pediatric population divided by age

• Type of Material: Article
• Authors: Cristina Interiano, Children's Healthcare of Atlanta; Sheicho Muze, Children's Healthcare of Atlanta; Brian Turner, Children's Healthcare of Atlanta; Mark Gonzalez, Emory University; Beverly Rogers, Emory University; Robert Jerris, Emory University; Elizabeth Weinzierl, Emory University; Mohamed Elkhalifa, Children's Healthcare of Atlanta; Van Leung-Pineda, Emory University
• Language: English
• Date: 2021-06-01
• Publisher: Emory University Libraries
• Publication Version: Final Published Version
• Copyright Statement: © 2021 The Authors. Published by Elsevier Inc.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.dib.2021.107110
• Title of Journal or Parent Work: Data in Brief
• Volume: 36
• Start Page: 107110
• End Page: 107110
• Grant/Funding Information: This study was supported by a grant from Abbott Laboratories.
• Keywords: SARS-CoV-2; serology; paediatrics; Nucleocapsid protein; IgM; COVID-19; IgG; Spike protein
• Research Categories: Health Sciences, Pathology

Abstract

Background: SARS-CoV-2 infection in children does not seem to follow the same pattern as in adults. Limited information is published on the level of antibody production and the duration of antibody response in children with COVID-19. Moreover, it is unknown if all children have a similar immune response to the infection, or if there are age dependent differences. In these data, we look at the IgM and IgG levels and duration of two age groups infected by the SARS-CoV-2 virus. Methods: Residual laboratory specimens from pediatric patients positive for SARS-CoV-2 infection were tested for IgM and IgG against SARS-CoV-2 using an automated Abbott ARCHITECT i1000. We tested 181 specimens from 41 patients with a positive molecular result. Data was grouped either as time after nucleic acid amplification test (NAAT) or time after symptom onset. Patient samples were divided into 2 age groups: 0 to 11 years old and 12 to 19 years old. The assays detect IgM against the spike protein and IgG against the nucleocapsid protein.